CN104603143A - 羟基红花黄色素a钠及其生产方法和制药用途 - Google Patents

羟基红花黄色素a钠及其生产方法和制药用途 Download PDF

Info

Publication number
CN104603143A
CN104603143A CN201380042130.5A CN201380042130A CN104603143A CN 104603143 A CN104603143 A CN 104603143A CN 201380042130 A CN201380042130 A CN 201380042130A CN 104603143 A CN104603143 A CN 104603143A
Authority
CN
China
Prior art keywords
sodium
carthamin yellow
hydroxyl radical
formula
radical carthamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201380042130.5A
Other languages
English (en)
Other versions
CN104603143B (zh
Inventor
叶凤起
蔡犇
卢敏
陈勇灵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Yongning Pharmaceutical Co Ltd
Original Assignee
Zhejiang Yongning Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Yongning Pharmaceutical Co Ltd filed Critical Zhejiang Yongning Pharmaceutical Co Ltd
Priority to CN201380042130.5A priority Critical patent/CN104603143B/zh
Publication of CN104603143A publication Critical patent/CN104603143A/zh
Application granted granted Critical
Publication of CN104603143B publication Critical patent/CN104603143B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

提供一种式I的羟基红花黄色素A钠化合物、其生产方法和制药用途。以天然药材红花为原料，通过提取、转钠盐、分离和纯化，得到纯度达到98.5％以上羟基红花黄色素A钠。羟基红花黄色素A钠在应用于抗血小板聚集、冠心病、心绞痛、急性脑缺血等血液循环障碍疾病的治疗上较羟基红花黄色素A更安全、有效、稳定，并且具有很好的水溶性和人体耐受性。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201380042130.5A 2013-02-07 2013-06-08 羟基红花黄色素a钠及其生产方法和制药用途 Active CN104603143B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201380042130.5A CN104603143B (zh) 2013-02-07 2013-06-08 羟基红花黄色素a钠及其生产方法和制药用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201310048476.8 2013-02-07
CN201310048476.8A CN103980239B (zh) 2013-02-07 2013-02-07 羟基红花黄色素a钠及其生产方法和用途
CN201380042130.5A CN104603143B (zh) 2013-02-07 2013-06-08 羟基红花黄色素a钠及其生产方法和制药用途
PCT/CN2013/000686 WO2014121424A1 (zh) 2013-02-07 2013-06-08 羟基红花黄色素a钠及其生产方法和制药用途

Publications (2)

Publication Number Publication Date
CN104603143A true CN104603143A (zh) 2015-05-06
CN104603143B CN104603143B (zh) 2016-12-14

Family

ID=51272434

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310048476.8A Active CN103980239B (zh) 2013-02-07 2013-02-07 羟基红花黄色素a钠及其生产方法和用途
CN201380042130.5A Active CN104603143B (zh) 2013-02-07 2013-06-08 羟基红花黄色素a钠及其生产方法和制药用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201310048476.8A Active CN103980239B (zh) 2013-02-07 2013-02-07 羟基红花黄色素a钠及其生产方法和用途

Country Status (7)

Country Link
US (1) US9243019B2 (zh)
EP (1) EP2829547B1 (zh)
JP (1) JP6133415B2 (zh)
KR (1) KR101801700B1 (zh)
CN (2) CN103980239B (zh)
IN (1) IN2014DN07091A (zh)
WO (1) WO2014121424A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104230864A (zh) * 2013-06-08 2014-12-24 浙江永宁药业股份有限公司 新的羟基红花黄色素a二价药用盐及其制备方法和用途
IN2014DN10592A (zh) * 2013-02-07 2015-09-11 Zhejiang Yongning Pharmaceutical Co Ltd
CN103980239B (zh) * 2013-02-07 2016-04-13 浙江永宁药业股份有限公司 羟基红花黄色素a钠及其生产方法和用途
CN105901923B (zh) * 2016-06-03 2017-10-24 佛山市迪赛纳科技有限公司 升降机构及包含升降机构的升降工作台和工作台升降方法
CN106214719B (zh) * 2016-08-31 2020-01-24 江西桔王药业有限公司 一种舒胸颗粒的制备方法
CN108392486B (zh) * 2018-01-23 2020-01-03 滨州医学院 羟基红花黄色素b在制备防治心肌缺血再灌注损伤的药物中的应用
CN113504199A (zh) * 2021-06-29 2021-10-15 苏州泽达兴邦医药科技有限公司 一种基于数据挖掘的红花提取液树脂纯化过程质量控制方法
CN113816933B (zh) * 2021-10-14 2024-02-09 北京悦康科创医药科技股份有限公司 一种羟基红花黄色素a的制备方法
CN113995729B (zh) * 2021-10-22 2022-11-18 北京悦康科创医药科技股份有限公司 羟基红花黄色素a口服半固体胶囊及其制备方法和应用
CN114098074A (zh) * 2021-11-09 2022-03-01 江南大学 羟基红花黄色素a在增强耐力中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1895317A (zh) * 2006-06-24 2007-01-17 太原华卫药业有限公司 一种红花注射液制备方法
CN101168539A (zh) * 2007-12-04 2008-04-30 哈药集团中药二厂 丹酚酸b和羟基红花黄色素a的提取方法及注射用丹红的制备方法
CN101195647A (zh) * 2006-12-06 2008-06-11 杨炜 羟基红花黄色素a及其制备方法和应用
CN103980239B (zh) * 2013-02-07 2016-04-13 浙江永宁药业股份有限公司 羟基红花黄色素a钠及其生产方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4510230B2 (ja) * 2000-05-26 2010-07-21 三栄源エフ・エフ・アイ株式会社 脱臭ベニバナ黄色素
CN1284794C (zh) 2002-08-17 2006-11-15 李盛学 羟基红花黄色素a的制备方法
CN100418522C (zh) * 2004-01-08 2008-09-17 山东瑞阳制药有限公司 大剂量的羟基红花黄色素a或其可药用盐的制药应用
JP2007063130A (ja) * 2004-03-31 2007-03-15 Kureha Corp 抗糖尿病用組成物
CN1935176B (zh) * 2005-09-23 2010-07-14 北京星昊医药股份有限公司 含有总红花黄色素的红花提取物的制备方法
CN101879155B (zh) * 2007-12-04 2011-12-21 哈药集团中药二厂 注射用丹红的制备方法
CN101215307B (zh) 2008-01-08 2010-11-10 山西大学 一种羟基红花黄色素a的制备方法
CN101640392A (zh) * 2009-07-15 2010-02-03 武汉科瑞德电力科技有限公司 35kV配电线路带电作业断引流线的作业方法
CN102675379B (zh) 2011-03-15 2015-08-19 河北以岭医药研究院有限公司 一种从红花中提取精制羟基红花黄色素a的方法
CN102702150B (zh) * 2012-06-19 2014-09-17 浙江永宁药业股份有限公司 一种羟基红花黄色素a的制备方法和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1895317A (zh) * 2006-06-24 2007-01-17 太原华卫药业有限公司 一种红花注射液制备方法
CN101195647A (zh) * 2006-12-06 2008-06-11 杨炜 羟基红花黄色素a及其制备方法和应用
CN101168539A (zh) * 2007-12-04 2008-04-30 哈药集团中药二厂 丹酚酸b和羟基红花黄色素a的提取方法及注射用丹红的制备方法
CN103980239B (zh) * 2013-02-07 2016-04-13 浙江永宁药业股份有限公司 羟基红花黄色素a钠及其生产方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
姚苗苗等，: "羟基红花黄色素A的研究进展.", 《中南药学》 *

Also Published As

Publication number Publication date
CN104603143B (zh) 2016-12-14
EP2829547A1 (en) 2015-01-28
CN103980239A (zh) 2014-08-13
WO2014121424A1 (zh) 2014-08-14
JP6133415B2 (ja) 2017-05-24
JP2015525232A (ja) 2015-09-03
IN2014DN07091A (zh) 2015-04-24
EP2829547A4 (en) 2015-11-18
US9243019B2 (en) 2016-01-26
CN103980239B (zh) 2016-04-13
US20150025030A1 (en) 2015-01-22
KR20150035491A (ko) 2015-04-06
EP2829547B1 (en) 2018-04-04
KR101801700B1 (ko) 2017-11-27

Similar Documents

Publication Publication Date Title
CN104603143B (zh) 羟基红花黄色素a钠及其生产方法和制药用途
CN100999470B (zh) 一种丹参丹酚酸a及制剂
US20070254847A1 (en) Pharmaceutical Composition Containing Steroidal Saponins, the Preparation Method and Use Thereof
CN101311160B (zh) 一种丹参丹酚酸a的制备方法
CN101230003B (zh) 一种丹参丹酚酸a的制备方法
CN104435034B (zh) 一种三七总皂苷及其制备方法
CN103980240B (zh) 新的羟基红花黄色素药用盐
CN104540811B (zh) 新的羟基红花黄色素药用盐
CN101759672B (zh) 丹参丹酚酸b
CN100496527C (zh) 一种灯盏细辛注射制剂的制备方法及其应用
CN110403928A (zh) 一种丹酚酸a盐复合物及其制备方法和应用
CN1994277B (zh) 一种丹参丹酚酸a固体制剂及其制备方法
CN103919759B (zh) 一种含有丹参素钠、丹参丹酚酸f的药物组合物及其制剂
CN102100721A (zh) 一种亳菊总黄酮的生产方法
CN102266386B (zh) 一种黄芩提取物及其制备方法和用途
CN1813709B (zh) 红花黄色素滴丸及其制造方法和应用
CN101768079A (zh) 化合物及药用用途
US9624254B2 (en) Hydroxysafflor yellow pharmaceutical salts
CN107056877A (zh) 一种甾体类化合物及其用途
CN101696166A (zh) 一种丹参丹酚酸a的制备方法
CN114805104A (zh) 一类氨基水杨酸类衍生物及其用途
CN101411736A (zh) 苣荬菜提取物在制备治疗缺血性心脑血管病新药中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Hydroxysafflower yellow a sodium and its production method and pharmaceutical use

Effective date of registration: 20210914

Granted publication date: 20161214

Pledgee: Industrial Commercial Bank of China Ltd. Taizhou Huangyan branch

Pledgor: ZHEJIANG YONGNING PHARMACEUTICAL Co.,Ltd.

Registration number: Y2021330001585